| 
printer friendly version
Idiosyncratic Liver Injury Associated
with Drugs (ILIAD)
The goal of the ILIAD protocol is to create a database
and bank of biological specimens (DNA, plasma, lymphocytes)
from individuals with severe drug-induced liver injury
(DILI) due to isoniazid (INH), phenytoin (Dilantin),
amoxicillin/clavulanate (Augmentin), or valproic
acid (Depakote) after January 1, 1994. This study
is funded by the NIH/NIDDK.
Study Design
- Telephone or personal interview of medical history
surrounding DILI event
- Single blood draw
- Participant receives $75
Please contact Suzanne Welch @ (734) 936-4886, toll free 1-866-UM liver, or
swelc@umich.edu
or Dr. Robert Fontana rfontana@med.umich.edu for referrals or questions.
A Multicenter, Longitudinal Study
of Drug- and CAM-Induced Liver Injury
The goal of this NIH study is to prospectively identify
bona fide cases of liver injury due to drugs and complementary
and alternative medications (CAM) within 6 months
of onset. Clinical data, blood, DNA, and urine will
be collected from affected patients and matched controls
for mechanistic and genetic studies.
Study Design
- All subjects have a baseline and 6-month follow-up
visit at the GCRC that includes: surveys, medical
history, blood and urine collection.
- Patients with liver injury at 6 months return
for 12- and 24-month visits.
Costs
- Costs of study lab tests provided by sponsor
(NIDDK).
- Subjects receive $50 for each completed study
visit.
Please contact Suzanne Welch @ (734) 936-4886, toll free 1-866-UM liver, or
swelc@umich.edu
or Dr. Robert Fontana rfontana@med.umich.edu for referrals or questions.
For more information see the following
websites
Drug-Induced
Liver Injury Network
NIH
funds network to study drug-induced liver injury
Press
Release: U-M helps lead national study of liver damage
1-866-UM-LIVER
swelc@umich.edu
|
